Can vedolizumab be given less often for Crohn's or colitis?
Treatments studied
Part of Digestive system clinical trials.
This research study tests whether taking vedolizumab injections less often (every 4 weeks instead of every 2 weeks) can still keep your Crohn's or colitis in remission. If you are already well-controlled on standard vedolizumab, this study may help you and others by reducing the number of injections needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have Crohn's disease or ulcerative colitis.
- Your disease is in remission (no active symptoms) and you've been off steroids for at least 6 months.
- You are currently taking vedolizumab injections (108 mg every other week) at a stable dose.
- You do not have an ostomy, short bowel syndrome, or a narrow section in your intestine.
- You are not pregnant, breastfeeding, or taking part in another research study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether people with Crohn’s disease or ulcerative colitis who are currently well-controlled can safely use less-frequent anti-TNF medicine. It may help reduce treatment intensity while keeping inflammation under control.
This study compares intravenous (IV) and under-the-skin (subcutaneous) biologic drugs for people with Crohn's disease or ulcerative colitis. It helps doctors understand if switching from the IV form to a shot is as effective and well-tolerated.
This trial tests whether a personalized dosing method (using your own drug levels) can help people with Crohn's or ulcerative colitis maintain better control with vedolizumab or ustekinumab. It aims to see if adjusting doses based on your individual needs leads to fewer flare-ups and better outcomes.
This study tests whether a weekly/regular skin injection version of vedolizumab can help adults with moderate to severe ulcerative colitis or Crohn’s disease who did not fully respond to other treatments or TNF blockers. It may help by moving you from an intravenous (IV) infusion to a self/clinic injection option.
This study tests the drug vedolizumab in adults with moderate to severe ulcerative colitis or Crohn's disease. It aims to see how well the medicine works in a community (non-hospital) setting.
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Hear when a new Inflammatory Bowel Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.